Search…

AbbVie to acquire Gilgamesh's new investigational drug bretisilocin for MDD.

26/08/2025

On August 26th, AbbVie announced that it has reached a definitive agreement with Gilgamesh Pharmaceuticals to acquire their investigational compound bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, for the treatment of moderate to severe depression.

Latest

2 m ago

The European Central Bank says foreign exchange reserves decreased by 500 million euros to 323.9 billion euros.

2 m ago

Spirit Airlines: Successfully completed the renewal of the International Air Transport Association's Operational Safety Audit.

3 m ago

US stocks rose 5% before the market on Tuesday. Morgan Stanley's latest research report states that NIO has strong ES8 orders. Although actual demand still depends on order conversion, the positive response supports market confidence, indicating that the group's monthly sales volume may reach 40,000 to 50,000 vehicles starting from October.

3 m ago

Before the market opened on Tuesday, US stocks rose 5% in pre-market trading. Morgan Stanley's latest research report stated that NIO has strong orders for the ES8, and although actual demand still depends on order conversion, the positive response supports market confidence, indicating that starting from October, the group's monthly sales volume may reach 40,000 to 50,000 vehicles.

3 m ago

Shenzhou Taiyue (300002.SZ) released its performance for the first half of the year, with a net profit attributable to shareholders of 509 million yuan, a decrease of 19.26%.

See all latest